<DOC>
	<DOCNO>NCT01038622</DOCNO>
	<brief_summary>The main objective proof-of-concept study demonstrate administration L-arginine , base suspect deficit monitor nasal nitric oxide measurement , improve immune function critically ill patient high risk nosocomial infection .</brief_summary>
	<brief_title>Directed Immuno Nutrition L-arginine Critically Ill Patients</brief_title>
	<detailed_description>Background : A meta-analysis demonstrated beneficial effect immuno nutrition surgical patient , lead half reduction incidence nosocomial infection ( HEYLAND DK , JAMA ; 2001 ) . This beneficial effect seem relate L-arginine content formula . In medical intensive care , improvement show , spite similar impairment immune response , could due heterogenous population . Our hypothesis beneficial effect could observe select patient medical intensive care unit . L-arginine semi-essential amino acid precursor nitric oxide ( NO ) synthesis . NO involved immune response regulation antimicrobial property , notably airways measure exhale gas . A decrease exhale nasal NO demonstrate critically ill patient , may suggest impairment production . Objectives : The aim study evaluate immune effect enteral L-arginine administration non surgical critically ill patient . These patient select base decrease nasal NO : direct immuno nutrition . The main objective demonstrate L-arginine administration , compare placebo administration , increase nasal NO enhances immune function ( increase HLA-DR expression monocyte , modification circulate Myeloid-Derived Suppressor Cells ( MDSC ) , decrease IL-6 , IL-17 plasmatic concentration ) : stimulation immune response . The secondary objective demonstrate safety L-arginine administration organ failure incidence nosocomial infection . This monocentric therapeutic trial , randomize double blind : standard enteral nutrition plus L-arginine ( 200 mg/kg/d 5 day admission ICU ) versus standard enteral nutrition plus placebo . Methods-Patients : Non surgical patient admit single medical intensive care unit , mechanical ventilation expect duration &gt; 2 day , decreased concentration nasal NO ( &lt; 60 ppb ) , without severe sepsis septic shock , enrol . On admission ( treatment ) , severity evaluate ( SAPS II SOFA score ) together assessment plasmatic L-arginine , cytokine ( IL-6 , IL-17 ) , MDSC , expression HLA-DR monocyte . The evaluation repeat day 4 ( treatment ) day 7 ( treatment ) . The enrolment 50 patient statistically enough demonstrate increase expression HLA-DR L-arginine group compare placebo group day 4 . Expected result perspective : The aim study demonstrate validity concept direct immune stimulation sole L-arginine medical intensive care unit , patient select base decrease exhale nasal NO concentration . This pathophysiological study necessary first step conduct large clinical trial aim demonstrate reduction nosocomial infection incidence L-arginine .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<criteria>Inclusion criterion : age &gt; 18 year medical patient ( absence recent surgery trauma ) initial aggression &lt; 5 day mechanically ventilate expected duration mechanical ventilation &gt; 2 day enteral nutrition absence previous immunosuppression nasal NO day 1 ICU stay &lt; 60 ppb Exclusion criterion : severe sepsis septic shock condition associate decrease nasal NO concentration ( cystic fibrosis , nasal polyposis , primary ciliary dyskinesia pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>L-arginine</keyword>
	<keyword>Nasal NO</keyword>
	<keyword>Nosocomial infection</keyword>
	<keyword>Immune function</keyword>
	<keyword>HLA-DR expression</keyword>
	<keyword>Critically ill</keyword>
	<keyword>Medical ICU patient</keyword>
</DOC>